CJC-1295 (Mod GRF 1-29)

Step	Weeks	Dose	Purpose
Weeks 1-2	—	100 mcg MOD-GRF 1-29 alone (no ipamorelin)	Isolate tolerance before adding a ghrelin-receptor agonist
Weeks 3-12	—	100 mcg MOD-GRF 1-29 + 200 mcg ipamorelin	Full GH-optimization protocol

Beginner Protocol

Intermediate Protocol

Advanced Protocol

Reconstitution and handling notes

Stacking Notes

Additional Dosage Notes

Evidence base: MOD-GRF 1-29 specifically has a smaller clinical trial footprint than CJC-1295 with DAC, because the commercial development program focused on the DAC variant (for convenient weekly dosing). The short-half-life form has extensive extrapolation from GHRH and sermorelin trials, plus supportive CJC-1295 pharmacodynamic data.

Clinical pharmacology

• Teichman et al., 2006, J Clin Endocrinol Metab - Phase 1 of CJC-1295 (DAC variant) in healthy adults established the GHRHR-agonist profile and reported a CJC-1295 half-life of ~6-8 days; PK/PD of the non-DAC form extrapolates from native GHRH and sermorelin.
• [Ionescu & Frohman, 2006, J Clin Endocrinol Metab] - Dose-response and IGF-1 elevation characterization.
• [Tesar, 2010] - Review of sermorelin (GRF 1-29) clinical data, which applies directly to MOD-GRF 1-29 given identical receptor affinity.

GHRH + GHRP synergy

• [Bowers et al., 1991, J Clin Endocrinol Metab] - Landmark demonstration of 3-5x GH amplification when GHRH and a ghrelin-receptor agonist are co-administered. The mechanistic foundation for all modern MOD-GRF + ipamorelin protocols.
• [Raun et al., 1998, Eur J Endocrinol] - Ipamorelin-specific synergy with GHRH analogs; no elevation of cortisol or prolactin.

GH and body composition

• Blackman et al., 2002, JAMA - 6-month randomized trial of recombinant GH in healthy older adults showed 1-3 kg lean mass gain and 2-3 kg fat loss, with meaningful side-effect burden (edema, carpal tunnel, insulin resistance). This is the benchmark for "what optimal GH elevation does to body composition."
• [Liu et al., 2007, Ann Intern Med] - Systematic review: GH in healthy elderly produces modest body composition changes with significant adverse events. Directly relevant to calibrating expectations for GH-secretagogue protocols.

Safety signal: IGF-1 and cancer

• [Chan et al., 1998, Science] - Higher plasma IGF-1 associated with increased prostate cancer risk in Physicians' Health Study.
• Renehan et al., 2004, Lancet - Meta-analysis of 21 studies: elevated IGF-1 associated with increased risk of prostate, colorectal, and premenopausal breast cancer. This is the dominant clinical safety consideration for all GH-secretagogues.
• [Jenkins et al., 2006, Clin Endocrinol] - Review of GH treatment and malignancy; no definitive increase in primary cancer incidence in adult GH replacement, but caution in active/remote malignancy.

What is NOT established

• Long-term (>2 year) safety of MOD-GRF 1-29 specifically - extrapolated from sermorelin, which has reasonable 5+ year safety data in pediatric GHD.
• Demonstrable longevity benefit in healthy adults - GH physiology argues against it (GH/IGF-1 axis signals accelerated aging in worm/mouse models).
• Muscle gain in strength-trained adults without resistance training - GH/IGF-1 elevation alone produces minimal hypertrophy without mechanical stimulus.

How to weight this evidence

Strong: receptor pharmacology, acute GH/IGF-1 response, GHRH-GHRP synergy. Moderate: intermediate-term body composition changes (1-6 months). Weak: long-term safety, longevity benefit, pure muscle-gain efficacy.

Expected / benign

• Injection-site reaction — mild redness, itching, small bump; 24-48 hour resolution
• Facial flushing / warmth 15-30 min post-injection (histamine release from GHRH action); typically diminishes after week 1-2
• Mild nausea in first week at higher doses
• Transient hunger increase (less than with MK-677 or ghrelin agonists)

Dose-dependent

• Water retention / mild peripheral edema — common in first 2-4 weeks, usually resolves
• Tingling or numbness in hands / carpal tunnel symptoms — dose-related; if persistent, reduce dose
• Morning lethargy or grogginess — from sub-optimal GH pulse timing; adjust to pre-bed dosing
• Joint stiffness — particularly in knees and fingers; dose-responsive
• Elevated fasting glucose — GH is counter-regulatory to insulin; modest at physiologic doses

Uncommon

• Headache — usually resolves with dose reduction or improved hydration
• Dizziness or orthostatic hypotension — rare
• Dream vividness — common with pre-bed dosing
• Injection-site lipodystrophy — with repeated same-site injection; rotate sites

Serious (dose- and duration-dependent)

• Insulin resistance / impaired glucose tolerance — chronic supraphysiologic GH elevation; rare at proper MOD-GRF 1-29 dosing but more common with DAC variant or MK-677
• Acromegaly-like features — not reported at physiologic doses; theoretical at very high chronic dosing
• Potential malignancy risk — see IGF-1 cancer meta-analysis (Renehan et al., 2004). Elevated IGF-1 is epidemiologically associated with increased prostate, colorectal, and premenopausal breast cancer risk
• Carpal tunnel syndrome — dose-responsive, typically reversible with dose reduction

Absolute contraindications

• Active malignancy (any type) — GH/IGF-1 signaling may promote tumor growth
• History of cancer within 5 years — insufficient data to stratify risk
• Diabetic retinopathy — IGF-1 promotes retinal neovascularization
• Pregnancy and lactation — no safety data
• Children with open growth plates — unintended growth acceleration

Relative contraindications

• Type 2 diabetes with poor control (HbA1c >8) — glucose worsening risk
• Severe hypothyroidism — suboptimal GH axis function; optimize thyroid first
• Intracranial pathology / elevated ICP — theoretical concern
• Active autoimmune disease — no direct evidence of harm, but insufficient data

Drug interactions

• Glucocorticoids — suppress GHRH response; minimize if possible
• High-dose SSRIs / antipsychotics — may blunt GH response
• Insulin / insulin secretagogues — GH raises glucose; monitor

Lab monitoring

• IGF-1 baseline and 8-12 weeks after starting
• Fasting glucose and HbA1c quarterly for first year, then annually
• Age-appropriate cancer screening per USPSTF guidelines (no different from non-users)